Epristeride is primarily used in the treatment of benign prostatic hyperplasia (BPH), a condition characterized by the enlargement of the prostate gland. It works by inhibiting the enzyme 5-alpha-reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). By reducing DHT levels, it helps to shrink the prostate and alleviate symptoms such as difficulty in urination, frequent urination, and incomplete bladder emptying. This makes it a valuable option for improving urinary flow and overall quality of life in men suffering from BPH. Additionally, its targeted mechanism of action minimizes the risk of affecting other hormonal pathways, making it a relatively specific treatment for this condition.